Product Information
Contents: Functional Grade Purified anti-human CD54 (ICAM-1)
Catalog Number: 16-0549
Sizes: 100 ug
Formulation: Phosphate buffer pH 7.2, 150 mM NaCl, No NaN3
Storage Conditions: Store at 4°C. Avoid repeated freeze/thaw cycles. KEEP CONTENTS STERILE.
Endotoxin Level: Less than 0.001 ng/ug antibody, as determined by the LAL assay.
Clone: HA58
Isotype: Mouse IgG1, κ
HLDA No.: VI A095
|
|
Surface staining of normal human peripheral blood cells with anti-human CD54 (HA58) PE. Appropriate isotype controls were used (open histogram). Cells in the lymphocyte population were used for analysis.
|
Questions? Please consult our answers to frequently asked questions at
http://www.ebioscience.com/faq.
Description
The HA58 monoclonal antibody reacts with human CD54 (InterCellular Adhesion Molecule-1, ICAM-1), a 90-110 kDa transmembrane glycoprotein expressed by monocytes, lymphocytes and endothelial cells. Expression of CD54 is upregulated on activated lymphocytes. Interaction of CD54 with its ligand CD11a is important in the inflammatory response.
Applications Reported
For research use only, not for diagnostic or therapeutic use. The HA58 antibody has been reported for use in flow cytometric analysis. HA58 has also been reported in blocking of
in vitro mixed lymphocyte reaction.
Applications Tested
The HA58 antibody has been tested by flow cytometric analysis of human peripheral blood leukocytes. This can be used at less than or equal to 0.25 μg per 100 μl blood (or per 1 million cells in 100 μl total staining volume). It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
References
Knapp, W., B. Dorken, et al. eds. 1989. Leucocyte Typing IV: White Cell Differentiation Antigens. Oxford University Press. New York.
Schlossman, S., L. Bloumsell, et al. eds 1995. Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press. New York.
Kishimoto, T., H. Kikutani, et al., eds. 1998. Leucocyte Typing VI: White Cell Differentiation Antigens. Garland Publishing Inc. London.
Kanwar JR, Berg RW, et al. 2003. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Ther. 10(6):468-76. (WB,
PubMed)
Bao J, Sato K, et al. 2001. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol. 281(6):H2612-8. (WB,
PubMed)
Davis DM, Chiu I, et al. 1999. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A. 96(26):15062-7. (IHC,
PubMed)
Related Products
Cat.
16-4714 Functional Grade Purified Mouse IgG1, K Isotype Control